Robert E. Bancroft - 17 Feb 2026 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Role
PRESIDENT & CEO, Director
Signature
/s/ Alexander Wilson, as Attorney-in-Fact, for Robert E. Bancroft
Issuer symbol
AEON
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
4
Filing time
19 Feb 2026, 20:40:27 UTC
Previous filing
16 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bancroft Robert E. PRESIDENT & CEO, Director C/O AEON BIOPHARMA, INC., 5 PARK PLAZA, SUITE 1750, IRVINE /s/ Alexander Wilson, as Attorney-in-Fact, for Robert E. Bancroft 19 Feb 2026 0002066370

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AEON Class A Common Stock Award $0 +3,000,000 +1694% $0.000000 3,177,103 17 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.